Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).

Vavricka, Stephan R

Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). [electronic resource] - Inflammatory bowel diseases Aug 2012 - 1523-30 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1536-4844

10.1002/ibd.21888 doi


Adalimumab
Adult
Aged
Aged, 80 and over
Anti-Inflammatory Agents--administration & dosage
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized--administration & dosage
Certolizumab Pegol
Crohn Disease--drug therapy
Female
Humans
Immunoglobulin Fab Fragments--administration & dosage
Immunosuppressive Agents--therapeutic use
Infliximab
Infusions, Intravenous
Injections, Subcutaneous
Male
Middle Aged
Patient Preference
Polyethylene Glycols--administration & dosage
Prognosis
Prospective Studies
Surveys and Questionnaires
Tumor Necrosis Factor-alpha--antagonists & inhibitors
Young Adult